Summit Therapeutics Inc.
Close on Oct 19, 2026
- Market cap
- $12.12B
- P/E (TTM)
- –
- Dividend yield
- –
About Summit Therapeutics
Pharmaceutical Preparations, SIC 2834
Summit Therapeutics Inc. is a biopharmaceutical company engaged in discovering, developing, and commercializing medicinal therapies in the oncology sector. Its principal lead investigational candidate is ivonescimab, a bispecific antibody designed to combine anti-angiogenesis and immunotherapy targeting VEGF and PD-1 pathways. The company focuses on developing treatments for patients with solid tumor malignancies, primarily evaluating clinical indications in non-small cell lung cancer and colorectal cancer.
The company holds licensed development and commercial rights for ivonescimab across multiple geographic territories, encompassing the United States, Canada, Europe, Japan, Latin America, the Middle East, and Africa. Its clinical trial programs operate across multiregional sites, including study locations in North America and Europe alongside partner-run trials in China. Over 4,000 trial participants have received ivonescimab globally. The provided excerpt does not identify the company's specific headquarters location.
Summary of the business section of Summit Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Summit Therapeutics Inc.
- Headquarters
- Miami, FL
- Address
- 601 Brickell Key Drive, Suite 1000 33131
- Phone
- (305) 203-2034
- Website
- smmttx.com
- Employees
- 265, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, San Jose, California
Stock & identifiers
- Ticker
- SMMT
- Exchange
- Nasdaq
- IPO date
- Mar 5, 2015
- Shares outstanding
- 798M, Jul 17, 2026
- Public float
- $2.48B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 1-for-5 reverse, Sep 18, 2020
- SEC CIK
- 1599298
- CUSIP
- 86627T108
- ISIN
- US86627T1088
- EIN
- 37-1979717
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Mahkam Zanganeh | Co-Chief Executive Officer, Director | 610,015,809 |
| Robert W. Duggan | Co-Chief Executive Officer, Director | 610,015,809 |
| Manmeet Singh Soni | COO and CFO, Director | 3,098,603 |
| Bhaskar Anand | Chief Accounting Officer | 159,751 |
| Jeff Huber | Director | 50,052 |
| Mostafa Ronaghi | Director | – |
| Kenneth A. Clark | Director | – |
| Robert F. Booth | Director | – |
| Yu Xia | Director | 32,057,147 |
| Alessandra Cesano | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Duggan | $172.38K | $172.38K | $249.13M | $372 | $120 |
| FY2025 Zanganeh | $246.05M | $233.11M | $249.13M | $372 | $120 |
| FY2024 Duggan | $158.61K | $158.61K | $2.51M | $380 | $114 |
| FY2024 Zanganeh | $1.16M | $228.31M | $2.51M | $380 | $114 |
| FY2023 Zanganeh | $20.56M | $30.06M | $12.05M | $56 | $116 |
| FY2022 Zanganeh | $1.24M | $3.79M | $1.36M | $90 | $112 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 265 total employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Dec 6, 2022 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| May 26, 2021 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Sep 18, 2020 | Delisting | Notice of delisting from exchange (Form 25) |
| Sep 17, 2020 | Name change | Name changed from Summit Therapeutics plc to Summit Therapeutics Inc. |
| Mar 5, 2015 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 2, 2015 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jan 30, 2015 | Name change | Name changed from Summit Corp plc to Summit Therapeutics plc |